Key Points
- CEO Martine Rothblatt sold 9,500 shares on May 1 at an average price of $570.58 for total proceeds of $5.42M, leaving her with 40,513 shares — about a 19% cut in her ownership valued at roughly $23.12M.
- United Therapeutics has a $25.47B market cap, a PE of 20.83 and a 52‑week range of $272.12–$607.89; it reported quarterly EPS of $7.70 (beat) with $790.2M revenue (slightly below estimates) and carries a Moderate Buy analyst consensus with a $601.50 target.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $570.58, for a total value of $5,420,510.00. Following the transaction, the chief executive officer owned 40,513 shares of the company's stock, valued at $23,115,907.54. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Stock Performance
Shares of NASDAQ:UTHR opened at $581.22 on Tuesday. The business's fifty day moving average price is $543.83 and its two-hundred day moving average price is $498.27. The stock has a market cap of $25.47 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 1.62 and a beta of 0.60. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $607.89.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business's revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the business earned $6.19 earnings per share. As a group, equities research analysts predict that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.
Institutional Investors Weigh In On United Therapeutics
Several large investors have recently made changes to their positions in the business. Avoro Capital Advisors LLC raised its stake in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP boosted its position in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. AQR Capital Management LLC increased its holdings in United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company's stock valued at $624,508,000 after purchasing an additional 295,221 shares in the last quarter. Janus Henderson Group PLC increased its holdings in United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company's stock valued at $387,801,000 after purchasing an additional 341,383 shares in the last quarter. Finally, Darwin Global Management Ltd. purchased a new position in United Therapeutics in the third quarter valued at about $317,617,000. Institutional investors and hedge funds own 94.08% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on UTHR. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an "equal weight" rating in a report on Tuesday, March 31st. Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an "outperform" rating in a research note on Thursday, February 26th. UBS Group increased their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a research note on Thursday, March 5th. Oppenheimer lifted their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, February 26th. Finally, Morgan Stanley increased their target price on United Therapeutics from $471.00 to $519.00 and gave the stock an "equal weight" rating in a research report on Friday, April 10th. Ten equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $601.50.
View Our Latest Stock Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
